vs
阿普塔集团（ATR）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是阿普塔集团的1.6倍（$1.5B vs $962.7M），Steris净利率更高（12.9% vs 7.7%，领先5.2%），阿普塔集团同比增速更快（13.5% vs 9.2%），Steris自由现金流更多（$199.5M vs $96.9M），过去两年Steris的营收复合增速更高（15.8% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
ATR vs STE — 直观对比
营收规模更大
STE
是对方的1.6倍
$962.7M
营收增速更快
ATR
高出4.4%
9.2%
净利率更高
STE
高出5.2%
7.7%
自由现金流更多
STE
多$102.6M
$96.9M
两年增速更快
STE
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $1.5B |
| 净利润 | $74.3M | $192.9M |
| 毛利率 | — | 43.8% |
| 营业利润率 | 11.0% | 18.3% |
| 净利率 | 7.7% | 12.9% |
| 营收同比 | 13.5% | 9.2% |
| 净利润同比 | -26.4% | 11.2% |
| 每股收益（稀释后） | $1.13 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRSTE
| Q4 25 | $962.7M | $1.5B | ||
| Q3 25 | $961.1M | $1.5B | ||
| Q2 25 | $966.0M | $1.4B | ||
| Q1 25 | $887.3M | $1.5B | ||
| Q4 24 | $848.1M | $1.4B | ||
| Q3 24 | $909.3M | $1.3B | ||
| Q2 24 | $910.1M | $1.3B | ||
| Q1 24 | $915.4M | $1.1B |
净利润ATRSTE
| Q4 25 | $74.3M | $192.9M | ||
| Q3 25 | $127.9M | $191.9M | ||
| Q2 25 | $111.7M | $177.4M | ||
| Q1 25 | $78.8M | $145.7M | ||
| Q4 24 | $100.9M | $173.5M | ||
| Q3 24 | $100.0M | $150.0M | ||
| Q2 24 | $90.5M | $145.4M | ||
| Q1 24 | $83.1M | $-1.4M |
毛利率ATRSTE
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 40.2% |
营业利润率ATRSTE
| Q4 25 | 11.0% | 18.3% | ||
| Q3 25 | 14.2% | 18.2% | ||
| Q2 25 | 14.9% | 17.7% | ||
| Q1 25 | 12.8% | 14.6% | ||
| Q4 24 | 14.2% | 17.9% | ||
| Q3 24 | 15.2% | 16.5% | ||
| Q2 24 | 13.8% | 14.5% | ||
| Q1 24 | 12.2% | 22.0% |
净利率ATRSTE
| Q4 25 | 7.7% | 12.9% | ||
| Q3 25 | 13.3% | 13.1% | ||
| Q2 25 | 11.6% | 12.8% | ||
| Q1 25 | 8.9% | 9.8% | ||
| Q4 24 | 11.9% | 12.7% | ||
| Q3 24 | 11.0% | 11.3% | ||
| Q2 24 | 9.9% | 11.4% | ||
| Q1 24 | 9.1% | -0.1% |
每股收益（稀释后）ATRSTE
| Q4 25 | $1.13 | $1.96 | ||
| Q3 25 | $1.92 | $1.94 | ||
| Q2 25 | $1.67 | $1.79 | ||
| Q1 25 | $1.17 | $1.48 | ||
| Q4 24 | $1.48 | $1.75 | ||
| Q3 24 | $1.48 | $1.51 | ||
| Q2 24 | $1.34 | $1.46 | ||
| Q1 24 | $1.23 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $423.7M |
| 总债务越低越好 | $1.1B | $1.9B |
| 股东权益账面价值 | $2.7B | $7.2B |
| 总资产 | $5.3B | $10.6B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资ATRSTE
| Q4 25 | $409.5M | $423.7M | ||
| Q3 25 | $264.8M | $319.2M | ||
| Q2 25 | $169.8M | $279.7M | ||
| Q1 25 | $136.8M | $171.7M | ||
| Q4 24 | $226.2M | $155.2M | ||
| Q3 24 | $327.9M | $172.2M | ||
| Q2 24 | $223.9M | $198.3M | ||
| Q1 24 | $201.1M | $207.0M |
总债务ATRSTE
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $546.0M | $1.9B | ||
| Q2 25 | $535.1M | $1.9B | ||
| Q1 25 | $561.2M | $1.9B | ||
| Q4 24 | $688.1M | $2.0B | ||
| Q3 24 | $822.7M | $2.2B | ||
| Q2 24 | $681.5M | $2.2B | ||
| Q1 24 | $680.4M | $3.1B |
股东权益ATRSTE
| Q4 25 | $2.7B | $7.2B | ||
| Q3 25 | $2.8B | $7.0B | ||
| Q2 25 | $2.7B | $7.0B | ||
| Q1 25 | $2.5B | $6.6B | ||
| Q4 24 | $2.5B | $6.4B | ||
| Q3 24 | $2.5B | $6.6B | ||
| Q2 24 | $2.4B | $6.4B | ||
| Q1 24 | $2.3B | $6.3B |
总资产ATRSTE
| Q4 25 | $5.3B | $10.6B | ||
| Q3 25 | $5.1B | $10.4B | ||
| Q2 25 | $4.9B | $10.4B | ||
| Q1 25 | $4.5B | $10.1B | ||
| Q4 24 | $4.4B | $10.0B | ||
| Q3 24 | $4.6B | $10.2B | ||
| Q2 24 | $4.5B | $10.1B | ||
| Q1 24 | $4.4B | $11.1B |
负债/权益比ATRSTE
| Q4 25 | 0.43× | 0.27× | ||
| Q3 25 | 0.20× | 0.27× | ||
| Q2 25 | 0.20× | 0.27× | ||
| Q1 25 | 0.22× | 0.29× | ||
| Q4 24 | 0.28× | 0.32× | ||
| Q3 24 | 0.32× | 0.33× | ||
| Q2 24 | 0.28× | 0.35× | ||
| Q1 24 | 0.29× | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $199.5M |
| 自由现金流率自由现金流/营收 | 10.1% | 13.3% |
| 资本支出强度资本支出/营收 | 9.0% | 6.6% |
| 现金转化率经营现金流/净利润 | 2.47× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $299.6M | $917.1M |
8季度趋势，按日历期对齐
经营现金流ATRSTE
| Q4 25 | $183.7M | $298.2M | ||
| Q3 25 | $177.6M | $287.8M | ||
| Q2 25 | $126.0M | $420.0M | ||
| Q1 25 | $82.7M | $260.8M | ||
| Q4 24 | $178.2M | $332.8M | ||
| Q3 24 | $229.3M | $250.7M | ||
| Q2 24 | $143.6M | $303.7M | ||
| Q1 24 | $92.3M | $254.8M |
自由现金流ATRSTE
| Q4 25 | $96.9M | $199.5M | ||
| Q3 25 | $114.3M | $201.3M | ||
| Q2 25 | $62.5M | $326.4M | ||
| Q1 25 | $25.9M | $189.9M | ||
| Q4 24 | $112.2M | $243.6M | ||
| Q3 24 | $162.7M | $148.8M | ||
| Q2 24 | $75.4M | $195.7M | ||
| Q1 24 | $16.7M | $163.3M |
自由现金流率ATRSTE
| Q4 25 | 10.1% | 13.3% | ||
| Q3 25 | 11.9% | 13.8% | ||
| Q2 25 | 6.5% | 23.5% | ||
| Q1 25 | 2.9% | 12.8% | ||
| Q4 24 | 13.2% | 17.8% | ||
| Q3 24 | 17.9% | 11.2% | ||
| Q2 24 | 8.3% | 15.3% | ||
| Q1 24 | 1.8% | 14.6% |
资本支出强度ATRSTE
| Q4 25 | 9.0% | 6.6% | ||
| Q3 25 | 6.6% | 5.9% | ||
| Q2 25 | 6.6% | 6.7% | ||
| Q1 25 | 6.4% | 4.8% | ||
| Q4 24 | 7.8% | 6.5% | ||
| Q3 24 | 7.3% | 7.7% | ||
| Q2 24 | 7.5% | 8.4% | ||
| Q1 24 | 8.3% | 8.2% |
现金转化率ATRSTE
| Q4 25 | 2.47× | 1.55× | ||
| Q3 25 | 1.39× | 1.50× | ||
| Q2 25 | 1.13× | 2.37× | ||
| Q1 25 | 1.05× | 1.79× | ||
| Q4 24 | 1.77× | 1.92× | ||
| Q3 24 | 2.29× | 1.67× | ||
| Q2 24 | 1.59× | 2.09× | ||
| Q1 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
